{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:04:23Z","timestamp":1793037863589,"version":"4.5.0"},"reference-count":335,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of progesterone and estrogen receptors and low (or absent) HER2 expression. TNBC accounts for 15-20% of all breast cancers. It is associated with younger age, a higher mutational burden, and an increased risk of recurrence and mortality. Standard treatment for TNBC primarily relies on cytotoxic agents, such as taxanes, anthracyclines, and platinum compounds for both early and advanced stages of the disease. Several targeted therapies, including bevacizumab and sunitinib, have failed to demonstrate significant clinical benefit in TNBC. The emergence of immune checkpoint inhibitors (ICI) has revolutionized cancer treatment. By stimulating the immune system, ICIs induce a durable anti-tumor response across various solid tumors. TNBC is a particularly promising target for treatment with ICIs due to the higher levels of tumor-infiltrating lymphocytes (TIL), increased PD-L1 expression, and higher mutational burden, which generates tumor-specific neoantigens that activate immune cells. ICIs administered as monotherapy in advanced TNBC yields only a modest response; however, response rates significantly improve when ICIs are combined with cytotoxic agents, particularly in tumors expressing PD-L1. Pembrolizumab is approved for use in both early and advanced TNBC in combination with standard chemotherapy. However, more research is needed to identify more potent biomarkers, and to better elucidate the synergism of ICIs with other targeted agents. In this review, we explore the challenges of immunotherapy in TNBC, examining the mechanisms of tumor progression mediated by immune cells within the tumor microenvironment, and the signaling pathways involved in both primary and acquired resistance. Finally, we provide a comprehensive overview of ongoing clinical trials underway to investigate novel immune-targeted therapies for TNBC.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1513421","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:11:08Z","timestamp":1734048668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review"],"prefix":"10.3389","volume":"15","author":[{"given":"Luc\u00eda","family":"Serrano Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"J\u00e1vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gi\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Leonor","family":"Fern\u00e1ndez-Murga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2023.04.002","article-title":"Molecular classification of breast cancer","volume":"18","author":"Roy","year":"2023","journal-title":"PET Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina breast cancer study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05727-x","article-title":"A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns","volume":"182","author":"Tzikas","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06767-1","article-title":"Varying outcomes of triple-negative breast cancer in different age groups\u2013prognostic value of clinical features and proliferation","volume":"196","author":"Vihervuori","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.03.10","article-title":"Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance","volume":"29","author":"Yu","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0968-0","article-title":"2011: the immune hallmarks of cancer","volume":"60","author":"Cavallo","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Sci (1979)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041728","article-title":"The myeloid cell compartment\u2014Cell by cell","volume":"37","author":"Bassler","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.immuni.2021.03.022","article-title":"Redefining macrophage and neutrophil biology in the metastatic cascade","volume":"54","author":"G\u00fc\u00e7","year":"2021","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.001","article-title":"Monocyte regulation in homeostasis and Malignancy","volume":"42","author":"Robinson","year":"2021","journal-title":"Trends Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Progress in experimental tumor research"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0041","article-title":"The emerging understanding of myeloid cells as partners and targets in tumor rejection","volume":"3","author":"Broz","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2997-3","article-title":"Tumor-associated macrophages: a short compendium","volume":"76","author":"Prenen","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbcan.2017.10.007","article-title":"Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1\/PD-L1 agents","volume":"1869","author":"Santoni","year":"2018","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukoc Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.08.013","article-title":"Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment","volume":"16","author":"Deryugina","year":"2014","journal-title":"Neoplasia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002875","article-title":"Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add5204","article-title":"Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis","volume":"8","author":"Gong","year":"2023","journal-title":"Sci Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659996","article-title":"Triple-negative breast cancer cells recruit neutrophils by secreting TGF-\u03b2 and CXCR2 ligands","volume":"12","author":"SenGupta","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02499","article-title":"Reactive oxygen species as regulators of MDSC-mediated immune suppression","volume":"9","author":"Ohl","year":"2018","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065208","article-title":"Defining the emergence of new immunotherapy approaches in breast cancer: role of myeloid-derived suppressor cells","volume":"24","author":"S\u00e1nchez-Le\u00f3n","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00291.x","article-title":"Arginase: an emerging key player in the mammalian immune system","volume":"158","author":"Munder","year":"2009","journal-title":"Br J Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081785","article-title":"Role of tumor-associated myeloid cells in breast cancer","volume":"9","author":"Cha","year":"2020","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105150","article-title":"Atovaquone suppresses triple-negative breast tumor growth by reducing immune-suppressive cells","volume":"22","author":"Gupta","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34345","article-title":"SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity","volume":"152","author":"Alcaraz","year":"2023","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41467-023-35793-w","article-title":"CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer","volume":"14","author":"Houthuijzen","year":"2023","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2020984","DOI":"10.1080\/2162402X.2021.2020984","article-title":"Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer","volume":"11","author":"Zheng","year":"2022","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104063","article-title":"Stromal cell diversity associated with immune evasion in human triple-negative breast cancer","volume":"39","author":"Wu","year":"2020","journal-title":"EMBO J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235878","article-title":"CD73-mediated immunosuppression is linked to a specific fibroblast population that paves the way for new therapy in breast cancer","volume":"13","author":"Magagna","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13050","article-title":"Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers","volume":"7","author":"Allaoui","year":"2016","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2116","article-title":"Fibroblast-derived IL33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type 2 immunity","volume":"80","author":"Shani","year":"2020","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1427","article-title":"Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer","volume":"82","author":"Timperi","year":"2022","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discovery"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34084","article-title":"Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis","volume":"128","author":"Malla","year":"2022","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693517","article-title":"Tumor-associated macrophages: A potential target for cancer therapy","volume":"11","author":"Tan","year":"2021","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4005","article-title":"Distinct role of macrophages in different tumor microenvironments","volume":"66","author":"Lewis","year":"2006","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-306","article-title":"The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients","volume":"12","author":"Medrek","year":"2012","journal-title":"BMC Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jss.2017.09.035","article-title":"Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients","volume":"222","author":"Zhang","year":"2018","journal-title":"J Surg Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","article-title":"Clinical significance of macrophage heterogeneity in human Malignant tumors","volume":"105","author":"Komohara","year":"2014","journal-title":"Cancer Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.08.010","article-title":"Tumor-associated macrophages in breast cancer: Innocent bystander or important player","volume":"70","author":"Qiu","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.772615","article-title":"Tumor-associated macrophages: key players in triple-negative breast cancer","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"15025","DOI":"10.1038\/npjbcancer.2015.25","article-title":"Tumor-associated macrophages: unwitting accomplices in breast cancer Malignancy","volume":"2","author":"Williams","year":"2016","journal-title":"NPJ Breast Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3892\/ijo.2022.5440","article-title":"PD-L1 mediates triple-negative breast cancer evolution via the regulation of TAM\/M2 polarization","volume":"61","author":"Meng","year":"2022","journal-title":"Int J Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s42003-023-04525-7","article-title":"Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases","volume":"6","author":"Hirano","year":"2023","journal-title":"Commun Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/srep09188","article-title":"Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer","volume":"5","author":"Hollm\u00e9n","year":"2015","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114126","article-title":"Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE","volume":"180","author":"Qiao","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302857","article-title":"The interaction between macrophages and triple-negative breast cancer cells induces ROS-mediated interleukin 1\u03b1 expression to enhance tumorigenesis and metastasis","volume":"10","author":"Hao","year":"2023","journal-title":"Advanced Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05336-3","article-title":"Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer","volume":"177","author":"Zeindler","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4161\/cc.9.9.11297","article-title":"The paradox of tumor-associated neutrophils: Fueling tumor growth with cytotoxic substances","volume":"9","author":"Houghton","year":"2010","journal-title":"Cell Cycle"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2017.18.10.2689","article-title":"Tumor-associated neutrophils in breast cancer subtypes","volume":"18","author":"Soto-Perez-de-Celis","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"B68","article-title":"Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer","volume":"14","author":"Lou","year":"2022","journal-title":"Am J Transl Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013340","article-title":"Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer","volume":"97","author":"Duan","year":"2018","journal-title":"Medicine"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005657","article-title":"Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor","volume":"10","author":"Arai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"361ra138","DOI":"10.1126\/scitranslmed.aag1711","article-title":"Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps","volume":"8","author":"Park","year":"2016","journal-title":"Sci Transl Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/8096764","article-title":"Prognostic implications of MALAT1 and BACH1 expression and their correlation with CTCs and mo-MDSCs in triple negative breast cancer and surgical management options","volume":"2022","author":"Elbasateeny","year":"2022","journal-title":"Int J Breast Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1038\/s41598-023-32554-z","article-title":"Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment","volume":"13","author":"Mehdizadeh","year":"2023","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/life13040998","article-title":"Identification of hub genes and biological mechanisms associated with non-alcoholic fatty liver disease and triple-negative breast cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Life"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.020","article-title":"Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"139","author":"Salvador-Coloma","year":"2020","journal-title":"Eur J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.01.009","article-title":"Sponge-like nano-system suppresses tumor recurrence and metastasis by restraining myeloid-derived suppressor cells-mediated immunosuppression and formation of pre-metastatic niche","volume":"158","author":"Xia","year":"2023","journal-title":"Acta Biomater"},{"key":"B80","article-title":"Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model","volume":"9","author":"Qian","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902280106","article-title":"G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models","volume":"106","author":"Shojaei","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99673","article-title":"[amp]]Delta;Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer","volume":"128","author":"Kumar","year":"2018","journal-title":"J Clin Invest"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081916","article-title":"PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS\/Notch\/Nodal Signaling","volume":"20","author":"Sprouse","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134290","article-title":"MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC","volume":"5","author":"Franklin","year":"2020","journal-title":"JCI Insight"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-019-0373-7","article-title":"Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms","volume":"21","author":"Kim","year":"2019","journal-title":"Nat Cell Biol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040702","article-title":"Dendritic cells are associated with prognosis and survival in breast cancer","volume":"11","author":"Szpor","year":"2021","journal-title":"Diagnostics"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11415","article-title":"CD11c-positive dendritic cells in triple-negative breast cancer","volume":"32","author":"Lee","year":"2018","journal-title":"In Vivo (Brooklyn)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.medj.2023.04.008","article-title":"CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer","volume":"4","author":"Wu","year":"2023","journal-title":"Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113342","article-title":"Plasmacytoid dendritic cell (pDC) infiltration correlate with tumor infiltrating lymphocytes, cancer immunity, and better survival in triple negative breast cancer (TNBC) more strongly than conventional dendritic cell (cDC)","volume":"12","author":"Oshi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0145-8","article-title":"Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific","volume":"19","author":"Michea","year":"2018","journal-title":"Nat Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102197","article-title":"Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.126912","article-title":"Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes","volume":"253","author":"Jing","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020238","article-title":"Modification of breast cancer milieu with chemotherapy plus dendritic cell vaccine: an approach to select best therapeutic strategies","volume":"11","author":"Mej\u00edas Sosa","year":"2023","journal-title":"Biomedicines"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030953","article-title":"Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges","volume":"12","author":"Wang","year":"2023","journal-title":"J Clin Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1149747","article-title":"Evaluation of triple negative breast cancer with heterogeneous immune infiltration","volume":"14","author":"Quintana","year":"2023","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071176","article-title":"Immune biomarkers in triple-negative breast cancer: improving the predictivity of current testing methods","volume":"13","author":"Porta","year":"2023","journal-title":"J Pers Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S285128","article-title":"Accumulation of regulatory T cells in triple negative breast cancer can boost immune disruption","volume":"13","author":"Zahran","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Sci (1979)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.160","article-title":"Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target","volume":"21","author":"Bohling","year":"2008","journal-title":"Modern Pathol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904418","article-title":"3D collagen fiber concentration regulates treg cell infiltration in triple negative breast cancer","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13058-015-0632-x","article-title":"Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study","volume":"17","author":"Miyashita","year":"2015","journal-title":"Breast Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.9036","article-title":"FOXP3 expression and overall survival in breast cancer","volume":"27","author":"Merlo","year":"2009","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-017-4161-4","article-title":"Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer","volume":"163","author":"Yeong","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B107","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/0284186X.2012.731520","article-title":"Prognostic impact of FOXP3 expression in triple-negative breast cancer","volume":"52","author":"Lee","year":"2013","journal-title":"Acta Oncol (Madr)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2019.04.004","article-title":"The predictive and prognostic value of Foxp3+\/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer","volume":"40","author":"Zhang","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01084-1","article-title":"Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast","volume":"27","author":"Jamiyan","year":"2020","journal-title":"Breast Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12282-017-0781-0","article-title":"The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)","volume":"25","author":"Tomioka","year":"2018","journal-title":"Breast Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103038","article-title":"Abundance of regulatory T cell (Treg) as a predictive biomarker for neoadjuvant chemotherapy in triple-negative breast cancer","volume":"12","author":"Oshi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.7150\/jca.14549","article-title":"PD-L1 expression is associated with tumor FOXP3 + Regulatory T-cell infiltration of breast cancer and poor prognosis of patient","volume":"7","author":"Li","year":"2016","journal-title":"J Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1042\/CS20191261","article-title":"Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer","volume":"134","author":"Guo","year":"2020","journal-title":"Clin Sci"},{"key":"B117","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13058-016-0783-4","article-title":"An immune stratification reveals a subset of PD-1\/LAG-3 double-positive triple-negative breast cancers","volume":"18","author":"Bottai","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262650","article-title":"Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer","volume":"17","author":"Zahran","year":"2022","journal-title":"PloS One"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2246319","DOI":"10.1080\/2162402X.2023.2246319","article-title":"CD39 + conventional CD4 + T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade","volume":"12","author":"Bossio","year":"2023","journal-title":"Oncoimmunology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/6452636","article-title":"Identification of cancer-associated fibroblast subtype of triple-negative breast cancer","volume":"2022","author":"Wang","year":"2022","journal-title":"J Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1038\/s41467-022-33598-x","article-title":"Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer","volume":"13","author":"Monteran","year":"2022","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.7150\/thno.68972","article-title":"FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer\u2014the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314937","article-title":"Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer","volume":"23","author":"Kudelova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B125","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-017-0621-z","article-title":"Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6\/STAT3, Notch and EGFR signaling pathways","volume":"16","author":"Ibrahim","year":"2017","journal-title":"Mol Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00804","article-title":"Notch-mediated tumor-stroma-inflammation networks promote invasive properties and CXCL8 expression in triple-negative breast cancer","volume":"10","author":"Liubomirski","year":"2019","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2101592118","article-title":"Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer","volume":"118","author":"Jaiswal","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B128","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12935-020-01727-5","article-title":"ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc","volume":"21","author":"Cheng","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0357","article-title":"Anti-jagged immunotherapy inhibits MDSCs and overcomes tumor-induced tolerance","volume":"77","author":"Sierra","year":"2017","journal-title":"Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/etm.2021.9666","article-title":"MicroRNA-598 inhibits the growth of triple negative breast cancer cells by targeting JAG1","volume":"21","author":"Han","year":"2021","journal-title":"Exp Ther Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1176","article-title":"Development of therapeutic anti-JAGGED1 antibodies for cancer therapy","volume":"18","author":"Masiero","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/biom13030459","article-title":"Novel scFv against Notch Ligand JAG1 Suitable for Development of Cell Therapies toward JAG1-Positive Tumors","volume":"13","author":"Silva","year":"2023","journal-title":"Biomolecules"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01756-y","article-title":"BCL9\/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080892","article-title":"Low dose of paclitaxel combined with XAV939 attenuates metastasis, angiogenesis and growth in breast cancer by suppressing wnt signaling","volume":"8","author":"Shetti","year":"2019","journal-title":"Cells"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28465","article-title":"Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo","volume":"234","author":"Mohammadi-Yeganeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1541-7786.MCR-18-0246","article-title":"Reversal of triple-negative breast cancer EMT by miR-200c decreases tryptophan catabolism and a program of immunosuppression","volume":"17","author":"Rogers","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679517","article-title":"IDO inhibition facilitates antitumor immunity of V\u03b39V\u03b42 T cells in triple-negative breast cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/jcrt.jcrt_2365_21","article-title":"The cytotoxic effects of indoleamine 2, 3-dioxygenase inhibitors on triple negative breast cancer cells upon tumor necrosis factor \u03b1 stimulation","volume":"19","author":"Bilir","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1953064","article-title":"The efficacy of indoximod upon stimulation with pro-inflammatory cytokines in triple-negative breast cancer cells","volume":"43","author":"Guney Eskiler","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121180","article-title":"A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2, 3-dioxygenase","volume":"279","author":"Guan","year":"2021","journal-title":"Biomaterials"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000368","article-title":"A phase I study of an IDO-1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer","volume":"44","author":"Kotecki","year":"2021","journal-title":"J Immunother"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002115","article-title":"MUC1-C integrates activation of the IFN-\u03b3 pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer","volume":"9","author":"Yamashita","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158219","article-title":"Addiction of cancer stem cells to MUC1-C in triple-negative breast cancer progression","volume":"23","author":"Yamashita","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B144","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41556-020-0495-y","article-title":"Loss of ELF5\u2013FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-\u03b3 signalling","volume":"22","author":"Singh","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05183-2","article-title":"Bazedoxifene is a novel IL-6\/GP130 inhibitor for treating triple-negative breast cancer","volume":"175","author":"Tian","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417","article-title":"Triple-negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence","volume":"9","author":"Almansour","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1095839","article-title":"Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy","volume":"13","author":"Loizides","year":"2022","journal-title":"Front Genet"},{"key":"B148","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1566524013666131118105216","article-title":"The molecular basis of notch signaling regulation: A complex simplicity","volume":"14","author":"Palermo","year":"2014","journal-title":"Curr Mol Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.692173","article-title":"Notch signalling in breast development and cancer","volume":"9","author":"Edwards","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4674","article-title":"A risk model of 10 aging-related genes for predicting survival and immune response in triple-negative breast cancer","volume":"11","author":"Yang","year":"2022","journal-title":"Cancer Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8442","article-title":"The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol Lett"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2021.12.015","article-title":"NOTCH expression variability and relapse of breast cancer in high-risk groups","volume":"364","author":"G\u00f3mez-Archila","year":"2022","journal-title":"Am J Med Sci"},{"key":"B154","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/BD-220041","article-title":"Clinical significance of Notch receptors in triple negative breast cancer","volume":"42","author":"Shah","year":"2023","journal-title":"Breast Dis"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2808","article-title":"Targeting notch signaling with a notch2\/notch3 antagonist (Tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency","volume":"21","author":"Yen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2012.990","article-title":"Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-\u03baB activity via the Notch-1 pathway","volume":"30","author":"Pan","year":"2012","journal-title":"Int J Mol Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-022-00677-6","article-title":"Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer","volume":"45","author":"Liu","year":"2022","journal-title":"Cell Oncol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/dna.2022.0578","article-title":"Targeting notch-driven cytokine secretion: novel therapies for triple negative breast cancer","volume":"42","author":"Marini","year":"2023","journal-title":"DNA Cell Biol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2016.08.019","article-title":"The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression","volume":"68","author":"Wang","year":"2016","journal-title":"Eur J Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0269","article-title":"Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses","volume":"70","author":"Wang","year":"2010","journal-title":"Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/nri3445","article-title":"Regulation of innate and adaptive immunity by Notch","volume":"13","author":"Radtke","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.2174\/1574892815666200929145236","article-title":"Anti-cancer effect of melatonin via downregulation of delta-like ligand 4 in estrogen-responsive breast cancer cells","volume":"15","author":"Rajabi","year":"2020","journal-title":"Recent Pat Anticancer Drug Discovery"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101080","article-title":"High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients","volume":"14","author":"Yuan","year":"2021","journal-title":"Transl Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11570","article-title":"Prognostic subcellular notch2, notch3 and jagged1 localization patterns in early triple-negative breast cancer","volume":"37","author":"Strati","year":"2017","journal-title":"Anticancer Res"},{"key":"B165","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/B978-0-12-416673-8.00013-7","article-title":"The functional role of notch signaling in triple-negative breast cancer","volume":"93","author":"Speiser","year":"2013","journal-title":"Vitamins and hormones"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00575","article-title":"Notch signaling regulates mitochondrial metabolism and NF-\u03baB activity in triple-negative breast cancer cells via IKK\u03b1-dependent non-canonical pathways","volume":"8","author":"Hossain","year":"2018","journal-title":"Front Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2017.03.014","article-title":"Expression of jagged1\/notch3 signaling pathway and their relationship with the tumor angiogenesis in TNBC","volume":"48","author":"Xue","year":"2017","journal-title":"Arch Med Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.12122\/j.issn.1673-4254.2022.07.21","article-title":"JAG1 promotes migration, invasion, and adhesion of triple-negative breast cancer cells by promoting angiogenesis","volume":"42","author":"Liu","year":"2022","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.07.006","article-title":"JAG1 enhances angiogenesis in triple-negative breast cancer through promoting the secretion of exosomal lncRNA MALAT1","volume":"10","author":"Liu","year":"2023","journal-title":"Genes Dis"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.12122\/j.issn.1673-4254.2023.09.10","article-title":"JAG1 affects monocytes-macrophages to reshape the pre-metastatic niche of triple-negative breast cancer through LncRNA MALAT1 in exosomes","volume":"43","author":"Xu","year":"2023","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.3c00099","article-title":"[amp]]gamma;-secretase inhibitor potentiates the activity of suberoylanilide hydroxamic acid by inhibiting its ability to induce epithelial to mesenchymal transition and stemness via notch pathway activation in triple-negative breast cancer cells","volume":"6","author":"Sen","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B172","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1186\/s12885-018-4653-6","article-title":"Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1230","article-title":"Single-cell analysis unveils the role of the tumor immune microenvironment and notch signaling in dormant minimal residual disease","volume":"82","author":"Janghorban","year":"2022","journal-title":"Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113845","article-title":"The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells","volume":"174","author":"Piwarski","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11797","article-title":"Wnt signaling pathway: A comprehensive review","volume":"46","author":"Hayat","year":"2022","journal-title":"Cell Biol Int"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-537","article-title":"Wnt signaling in triple negative breast cancer is associated with metastasis","volume":"13","author":"Dey","year":"2013","journal-title":"BMC Cancer"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.902870","article-title":"Cancer-associated fibroblasts autophagy enhances progression of triple-negative breast cancer cells","volume":"23","author":"Wang","year":"2017","journal-title":"Med Sci Monitor"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2104162118","article-title":"Drivers and suppressors of triple-negative breast cancer","volume":"118","author":"Wu","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-170708","article-title":"Tumor-infiltrating lymphocytes are associated with \u03b2-catenin overexpression in breast cancer","volume":"21","author":"Ma","year":"2018","journal-title":"Cancer Biomarkers"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003409","article-title":"Induction of wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: A retrospective study","volume":"10","author":"Klinke","year":"2014","journal-title":"PloS Comput Biol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7578","article-title":"Andrographolide suppresses breast cancer progression by modulating tumor-associated macrophage polarization through the Wnt\/\u03b2 -catenin pathway","volume":"36","author":"Li","year":"2022","journal-title":"Phytother Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578963","article-title":"Analysis of N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer","volume":"10","author":"Gong","year":"2020","journal-title":"Front Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0700-2","article-title":"WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer","volume":"38","author":"Castagnoli","year":"2019","journal-title":"Oncogene"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030457","article-title":"Cytotoxic lymphocyte-related gene signature in triple-negative breast cancer","volume":"13","author":"Han","year":"2023","journal-title":"J Pers Med"},{"key":"B186","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat Commun"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl4414","article-title":"Immature natural killer cells promote progression of triple-negative breast cancer","volume":"15","author":"Thacker","year":"2023","journal-title":"Sci Transl Med"},{"key":"B188","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13046-019-1231-y","article-title":"Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing \u03b2-catenin","volume":"38","author":"Shen","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B189","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1038\/s41467-020-17770-9","article-title":"ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt\/\u03b2-catenin activation to enhance drug resistance in breast cancers","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S255419","article-title":"MiR-27a-3p targeting GSK3\u03b2 Promotes triple-negative breast cancer proliferation and migration through wnt\/\u03b2-catenin pathway","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0087","article-title":"The interferon-gamma paradox in cancer","volume":"39","author":"Zaidi","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-\u03b3 in cancer","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197178","article-title":"Prognostic significance of interferon-\u03b3 and its signaling pathway in early breast cancer depends on the molecular subtypes","volume":"21","author":"Heimes","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1700","article-title":"Interferon gamma in cancer immunotherapy","volume":"7","author":"Ni","year":"2018","journal-title":"Cancer Med"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010089","article-title":"The dark side of IFN-\u03b3: its role in promoting cancer immunoevasion","volume":"19","author":"Mojic","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2021.101053","article-title":"Identification of genes modulated by interferon gamma in breast cancer cells","volume":"27","author":"Tecalco-Cruz","year":"2021","journal-title":"Biochem Biophys Rep"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1454","article-title":"Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer","volume":"9","author":"Sceneay","year":"2019","journal-title":"Cancer Discovery"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223698","article-title":"The role of IL-6 in cancer cell invasiveness and metastasis\u2014Overview and therapeutic opportunities","volume":"11","author":"Ra\u0161kov\u00e1","year":"2022","journal-title":"Cells"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin Sci"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.09.177","article-title":"The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer","volume":"108","author":"Masjedi","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-015-0529-2","article-title":"Interleukin-6 and pro inflammatory status in the breast tumor microenvironment","volume":"13","author":"Sanguinetti","year":"2015","journal-title":"World J Surg Oncol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.05.006","article-title":"Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells","volume":"15","author":"Labovsky","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10833","article-title":"Circulating interleukin-6 predicts survival in patients with metastatic breast cancer","volume":"103","author":"Salgado","year":"2003","journal-title":"Int J Cancer"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26699","article-title":"HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1\u03b2","volume":"10","author":"Tawara","year":"2019","journal-title":"Oncotarget"},{"key":"B210","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01285","article-title":"Kinome-wide siRNA screening identifies src-enhanced resistance of chemotherapeutic drugs in triple-negative breast cancer cells","volume":"9","author":"Tzeng","year":"2018","journal-title":"Front Pharmacol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0132-4","article-title":"Interaction between STAT3 and GLI1\/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer","volume":"37","author":"Sirkisoon","year":"2018","journal-title":"Oncogene"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-018-0218-0","article-title":"Hypoxia induces the acquisition of cancer stem-like phenotype via upregulation and activation of signal transducer and activator of transcription-3 (STAT3) in MDA-MB-231, a triple negative breast cancer cell line","volume":"11","author":"Soleymani Abyaneh","year":"2018","journal-title":"Cancer Microenviron"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-1194","article-title":"STAT3 targets ERR-\u03b1 to promote epithelial\u2013mesenchymal transition, migration, and invasion in triple-negative breast cancer cells","volume":"17","author":"Ma","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6014","article-title":"High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients","volume":"12","author":"Morrow","year":"2023","journal-title":"Cancer Med"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3390\/cells11101705","article-title":"Interleukin-6 signaling in triple negative breast cancer cells elicits the annexin A1\/formyl peptide receptor 1 axis and affects the tumor microenvironment","volume":"11","author":"Vecchi","year":"2022","journal-title":"Cells"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S426849","article-title":"The therapeutic effects of MUC1-C shRNA@Fe3O4 magnetic nanoparticles in alternating magnetic fields on triple-negative breast cancer","volume":"18","author":"Li","year":"2023","journal-title":"Int J Nanomed"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15164","article-title":"Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer","volume":"9","author":"Li","year":"2023","journal-title":"Heliyon"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00978-y","article-title":"The multifaceted role of MUC1 in tumor therapy resistance","volume":"23","author":"Jin","year":"2022","journal-title":"Clin Exp Med"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.158","article-title":"MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches","volume":"32","author":"Kufe","year":"2013","journal-title":"Oncogene"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgaa082","article-title":"MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment","volume":"41","author":"Kufe","year":"2020","journal-title":"Carcinogenesis"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1636","article-title":"MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer","volume":"78","author":"Maeda","year":"2018","journal-title":"Cancer Res"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-018-0013-x","article-title":"Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer","volume":"3","author":"Hiraki","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039432","article-title":"Cooperative interaction between the MUC1-C oncoprotein and the rab31 GTPase in estrogen receptor-positive breast cancer cells","volume":"7","author":"Jin","year":"2012","journal-title":"PloS One"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1038\/srep26643","article-title":"MUC1-C stabilizes MCL-1 in the oxidative stress response of triple-negative breast cancer cells to BCL-2 inhibitors","volume":"6","author":"Hiraki","year":"2016","journal-title":"Sci Rep"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112580","article-title":"Targeting MUC1-C suppresses chronic activation of cytosolic nucleotide receptors and STING in triple-negative breast cancer","volume":"14","author":"Yamashita","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1034","article-title":"MUC1-C activates the nuRD complex to drive dedifferentiation of triple-negative breast cancer cells","volume":"79","author":"Hata","year":"2019","journal-title":"Cancer Res"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0156","article-title":"Targeting MUC1-C inhibits TWIST1 signaling in triple-negative breast cancer","volume":"18","author":"Hata","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108168","article-title":"MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells","volume":"26","author":"Yamashita","year":"2023","journal-title":"iScience"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176820","article-title":"MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer","volume":"12","author":"Goode","year":"2017","journal-title":"PloS One"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00614-0","article-title":"Comprehensive metabolomics expands precision medicine for triple-negative breast cancer","volume":"32","author":"Xiao","year":"2022","journal-title":"Cell Res"},{"key":"B233","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","article-title":"Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets","volume":"33","author":"Gong","year":"2021","journal-title":"Cell Metab"},{"key":"B234","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41598-019-57068-5","article-title":"Metabolomics-based discovery of molecular signatures for triple negative breast cancer in Asian female population","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1002\/prca.202200042","article-title":"Two effective models based on comprehensive lipidomics and metabolomics can distinguish BC versus HCs, and TNBC versus non-TNBC","volume":"17","author":"Jin","year":"2023","journal-title":"Proteomics Clin Appl"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00038","article-title":"Triple negative breast cancer detection using LC\u2013MS\/MS lipidomic profiling","volume":"19","author":"Eghlimi","year":"2020","journal-title":"J Proteome Res"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13070865","article-title":"Metabolomics analysis reveals altered metabolic pathways and response to doxorubicin in drug-resistant triple-negative breast cancer cells","volume":"13","author":"Rushing","year":"2023","journal-title":"Metabolites"},{"key":"B238","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12935-023-03124-0","article-title":"Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics","volume":"23","author":"Carneiro","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3242","article-title":"Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer","volume":"81","author":"Evans","year":"2021","journal-title":"Cancer Res"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.708052","article-title":"NMR-based metabolomics analysis predicts response to neoadjuvant chemotherapy for triple-negative breast cancer","volume":"8","author":"He","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B241","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11306-023-02024-8","article-title":"Metabolomics unravels subtype-specific characteristics related to neoadjuvant therapy response in breast cancer patients","volume":"19","author":"Zapater-Moros","year":"2023","journal-title":"Metabolomics"},{"key":"B242","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13058-020-01351-1","article-title":"Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression","volume":"22","author":"Heng","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753477","article-title":"Slit2-mediated metabolic reprogramming in bone marrow-derived macrophages enhances antitumor immunity","volume":"12","author":"Kaul","year":"2021","journal-title":"Front Immunol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041211","article-title":"Metabolic reprogramming of breast tumor-educated macrophages revealed by NMR metabolomics","volume":"15","author":"Dias","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1038\/478192a","article-title":"Why tumours eat tryptophan","volume":"478","author":"Prendergast","year":"2011","journal-title":"Nature"},{"key":"B246","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-016-4027-1","article-title":"Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer","volume":"161","author":"Gautam","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B247","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-016-0559-6","article-title":"Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling","volume":"15","author":"Gautam","year":"2016","journal-title":"Mol Cancer"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-022-01391-9","article-title":"Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1","volume":"29","author":"C\u0131nar","year":"2022","journal-title":"Breast Cancer"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2011","article-title":"A TDO2-ahR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer","volume":"75","author":"D\u2019Amato","year":"2015","journal-title":"Cancer Res"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.03.013","article-title":"Comprehensive analysis of the expressionand prognosis for TDO2 in breast cancer","volume":"17","author":"Liu","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0362","article-title":"A role for tryptophan-2,3-dioxygenase in CD8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma","volume":"17","author":"Greene","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"B253","article-title":"Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer","volume":"32","author":"Sakurai","year":"2005","journal-title":"Gan To Kagaku Ryoho"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2003.12.004","article-title":"Indoleamine 2,3-dioxygenase activity and l-tryptophan transport in human breast cancer cells","volume":"1661","author":"Travers","year":"2004","journal-title":"Biochim Biophys Acta (BBA) - Biomembranes"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S184221","article-title":"Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan","volume":"11","author":"Asghar","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1859-3","article-title":"IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis","volume":"35","author":"Isla Larrain","year":"2014","journal-title":"Tumor Biol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106506","article-title":"Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer","volume":"84","author":"Wei","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0061-3","article-title":"IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1","volume":"31","author":"Dill","year":"2018","journal-title":"Modern Pathol"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10482","article-title":"Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer","volume":"8","author":"Alkhayyal","year":"2022","journal-title":"Heliyon"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J Clin Invest"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5952-4_39","article-title":"Implications of interferon-induced tryptophan catabolism in cancer, autoimmune diseases and aids","volume":"294","author":"Brown","year":"1991","journal-title":"Advances in experimental medicine and biology"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.11.3521","article-title":"Association between cyclooxygenase-2 and indoleamine 2,3-dioxygenase expression in breast cancer patients from Pakistan","volume":"20","author":"Asghar","year":"2019","journal-title":"Asian Pacific J Cancer Prev"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i12.1018","article-title":"Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients","volume":"11","author":"Asghar","year":"2020","journal-title":"World J Clin Oncol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1089\/cmb.2019.0340","article-title":"Modeling multiplexed images with spatial-LDA reveals novel tissue microenvironments","volume":"27","author":"Chen","year":"2020","journal-title":"J Comput Biol"},{"key":"B265","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/15384047.2018.1450116","article-title":"Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer","volume":"19","author":"Li","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400833","article-title":"Noncanonical NF-\u03baB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer","volume":"193","author":"Yu","year":"2014","journal-title":"J Immunol"},{"key":"B267","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3655","article-title":"Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy","volume":"16","author":"Vollebergh","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B268","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/cancers16061184","article-title":"TP53 and\/or BRCA1 mutations based on ctDNA analysis as prognostic biomarkers for primary triple-negative breast cancer","volume":"16","author":"Arimura","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03541-1","article-title":"Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology","volume":"26","author":"Colomer","year":"2024","journal-title":"Clin Trans Oncol"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3185-2","article-title":"The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis","volume":"148","author":"Ibrahim","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.985886","article-title":"Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer","volume":"13","author":"Aparicio","year":"2022","journal-title":"Front Immunol"},{"key":"B274","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007336","article-title":"Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer","volume":"11","author":"Brito Baleeiro","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-06929-9","article-title":"A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer","volume":"199","author":"Yam","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"B278","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.1038\/s41467-023-42479-w","article-title":"Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"New Engl J Med"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.506","article-title":"Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2","volume":"35","author":"Nanda","year":"2017","journal-title":"J Clin Oncol"},{"key":"B281","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","article-title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial","volume":"14","author":"Buisseret","year":"2023","journal-title":"Nat Commun"},{"key":"B282","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003427","article-title":"Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer","volume":"10","author":"Anders","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B285","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.CCR-23-1349","article-title":"Phase II clinical trial of pembrolizumab and chemotherapy reveals distinct transcriptomic profiles by radiologic response in metastatic triple-negative breast cancer","volume":"30","author":"Wilkerson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4726","article-title":"Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase ib\/II study","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"New Engl J Med"},{"key":"B288","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12916-022-02527-6","article-title":"A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"B289","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B290","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","article-title":"Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"B291","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","article-title":"Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)","volume":"171","author":"Ozaki","year":"2022","journal-title":"Eur J Cancer"},{"key":"B292","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"B293","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","article-title":"Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (Atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0145","article-title":"A pilot study of neoadjuvant nivolumab, ipilimumab, and intralesional oncolytic virotherapy for HER2-negative breast cancer","volume":"3","author":"Nguyen","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0622","article-title":"A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer","volume":"28","author":"Sun","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100884","article-title":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","volume":"8","author":"Hecht","year":"2023","journal-title":"ESMO Open"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14510","article-title":"Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer","volume":"111","author":"Toh","year":"2020","journal-title":"Cancer Sci"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e14513","article-title":"Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors","volume":"39","author":"Gutierrez","year":"2021","journal-title":"J Clin Oncol"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS603","article-title":"NSABP B-59\/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo","volume":"36","author":"Geyer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096343056240828190900","article-title":"Antibody-drug conjugates (ADCs): A novel therapy for triple-negative breast cancer (TNBC)","volume":"25","author":"Gupta","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS596","article-title":"KEYLYNK-009: A phase II\/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","volume":"38","author":"Rugo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B305","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.09.004","article-title":"Bispecific antibodies for triple negative breast cancer","volume":"7","author":"Dees","year":"2021","journal-title":"Trends Cancer"},{"key":"B307","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1186\/s12967-024-05689-4","article-title":"Targeting CD276 for T cell-based immunotherapy of breast cancer","volume":"22","author":"Hagelstein","year":"2024","journal-title":"J Transl Med"},{"key":"B308","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B309","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-021-06423-0","article-title":"Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody\u2013drug conjugates and bispecific antibodies","volume":"191","author":"Torres","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2015-203089","article-title":"Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer","volume":"69","author":"Lee","year":"2016","journal-title":"J Clin Pathol"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05548-y","article-title":"Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers","volume":"180","author":"Seow","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1544-9","article-title":"Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue","volume":"63","author":"Sili\u0146a","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1364506","article-title":"Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B314","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","article-title":"Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B315","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: A race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfusion Med Hemother"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B317","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: A new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"B318","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front Immunol"},{"key":"B319","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051597","article-title":"The new frontier of immunotherapy: chimeric antigen receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast cancer","volume":"15","author":"Schepisi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008668","article-title":"First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors","volume":"12","author":"Wermke","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2678","article-title":"A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers","volume":"40","author":"Norberg","year":"2022","journal-title":"J Clin Oncol"},{"key":"B323","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/cells10051020","article-title":"In vitro evaluation of CD276-CAR NK-92 functionality, migration and invasion potential in the presence of immune inhibitory factors of the tumor microenvironment","volume":"10","author":"Grote","year":"2021","journal-title":"Cells"},{"key":"B324","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1423","article-title":"Characterization of an immunogenic mutation in a patient with metastatic triple-negative breast cancer","volume":"23","author":"Assadipour","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669965","article-title":"Autologous dendritic cells in combination with chemotherapy restore responsiveness of T cells in breast cancer patients: A single-arm phase I\/II trial","volume":"12","author":"Bernal-Est\u00e9vez","year":"2021","journal-title":"Front Immunol"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e14302","article-title":"Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1)","volume":"37","author":"Bae","year":"2019","journal-title":"J Clin Oncol"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102324","article-title":"Targeting brain metastases in breast cancer","volume":"103","author":"Corti","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06602-7","article-title":"Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"195","author":"O\u2019Shaughnessy","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05995-7","article-title":"Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase","volume":"185","author":"Sachdev","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2091","article-title":"Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial","volume":"42","author":"Bartsch","year":"2024","journal-title":"J Clin Oncol"},{"key":"B331","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05405-7","article-title":"Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse","volume":"178","author":"Siddappa","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B332","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0835","article-title":"Cyclophosphamide enhances cancer antibody immunotherapy in the resistant bone marrow niche by modulating macrophage fc\u03b3R expression","volume":"7","author":"Roghanian","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B333","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-023-01619-2","article-title":"The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy","volume":"25","author":"Wimberger","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1042773","article-title":"Symptomatic bone marrow metastases in breast cancer: A retrospective cohort study","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B335","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2707208","article-title":"Combined analysis of disseminated tumor cells (DTCs) and circulating tumor DNA (ctDNA) in a patient suffering from triple negative breast cancer revealed elevated risk","volume":"27","author":"Nel","year":"2022","journal-title":"Front Bioscience-Landmark"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1513421\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:11:24Z","timestamp":1734048684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1513421\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":335,"alternative-id":["10.3389\/fimmu.2024.1513421"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1513421","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"article-number":"1513421"}}